Claims for Patent: 10,555,924

Summary for Patent: 10,555,924

Title:	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Abstract:	In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
Inventor(s):	Soni; Paresh (Mystic, CT)
Assignee:	Amarin Pharmaceuticals Ireland Limited (IE)
Application Number:	16/502,621
Patent Claims:	1. A method of reducing risk of unstable angina in a subject with established cardiovascular disease, the method comprising administering to said subject about 4 g of ethyl icosapentate per day for a period effective to reduce risk of unstable angina in the subject. 2. The method of claim 1, wherein the subject has a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL and a fasting baseline LDL-C level of about 40 mg/dL to about 100 mg/dL. 3. The method of claim 1, wherein the ethyl icosapentate is present in a pharmaceutical composition and the ethyl icosapentate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition. 4. The method of claim 1 wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules. 5. The method of claim 1, wherein said period ends at least 2 years after initial administration of the ethyl icosapentate to the subject. 6. The method of claim 1 wherein the subject is on statin therapy. 7. The method of claim 1, wherein the subject has a triglyceride level of at least 135 mg/dL and is on statin therapy.